These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 38489873

  • 1. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer.
    Velázquez-Vega LE, Rivera-Robles M, Sánchez-Álvarez AO, Vivas-Mejía PE, Aponte-Reyes M, Cruz-Collazo AM, Grafals-Ruiz N, Dorta-Estremera S, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Transl Oncol; 2024 Jun; 44():101928. PubMed ID: 38489873
    [Abstract] [Full Text] [Related]

  • 2. Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42.
    Medina JI, Cruz-Collazo A, Del Mar Maldonado M, Gascot TM, Borrero-Garcia LD, Cooke M, Kazanietz MG, O'Farril EH, Vlaar CP, Dharmawardhane S.
    Cancer Res Commun; 2022 Dec; 2(12):1711-1726. PubMed ID: 36861094
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer.
    Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2021 Dec; 20(12):2420-2432. PubMed ID: 34607932
    [Abstract] [Full Text] [Related]

  • 4. Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models.
    Torres-Sanchez A, Rivera-Robles M, Castillo-Pichardo L, Martínez-Ferrer M, Dorta-Estremera SM, Dharmawardhane S.
    Front Oncol; 2023 Dec; 13():1152458. PubMed ID: 37397366
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer.
    Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O'Farrill E, Borrero-Garcia LD, Forestier-Roman I, Gerena Y, Blanco M, Rivera-Robles MJ, Rodriguez-Medina JR, Cubano LA, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2017 May; 16(5):805-818. PubMed ID: 28450422
    [Abstract] [Full Text] [Related]

  • 6. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.
    Breast Cancer Res; 2017 Jun 30; 19(1):74. PubMed ID: 28666462
    [Abstract] [Full Text] [Related]

  • 7. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y, Wang Z, Jiang Y, Yang C.
    Cancer Lett; 2011 Dec 26; 313(1):54-63. PubMed ID: 21943825
    [Abstract] [Full Text] [Related]

  • 8. Targeting Rac and Cdc42 GEFs in Metastatic Cancer.
    Maldonado MDM, Medina JI, Velazquez L, Dharmawardhane S.
    Front Cell Dev Biol; 2020 Dec 26; 8():201. PubMed ID: 32322580
    [Abstract] [Full Text] [Related]

  • 9. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    Borrero-García LD, Del Mar Maldonado M, Medina-Velázquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S.
    BMC Cancer; 2021 Jun 01; 21(1):652. PubMed ID: 34074257
    [Abstract] [Full Text] [Related]

  • 10. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
    Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Marchetti JM.
    Eur J Pharm Biopharm; 2017 Jun 01; 115():159-167. PubMed ID: 28257810
    [Abstract] [Full Text] [Related]

  • 11. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 01; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 12. Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice.
    Reig-López J, Maldonado MDM, Merino-Sanjuan M, Cruz-Collazo AM, Ruiz-Calderón JF, Mangas-Sanjuán V, Dharmawardhane S, Duconge J.
    Pharmaceutics; 2020 Oct 15; 12(10):. PubMed ID: 33076517
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography-Tandem Mass Spectrometry.
    Maldonado MDM, Rosado-González G, Bloom J, Duconge J, Ruiz-Calderón JF, Hernández-O'Farrill E, Vlaar C, Rodríguez-Orengo JF, Dharmawardhane S.
    ACS Omega; 2019 Nov 05; 4(19):17981-17989. PubMed ID: 31720502
    [Abstract] [Full Text] [Related]

  • 14. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K.
    Cancer Med; 2019 Mar 05; 8(3):1258-1268. PubMed ID: 30701699
    [Abstract] [Full Text] [Related]

  • 15. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
    Rodríguez-Serrano F, Mut-Salud N, Cruz-Bustos T, Gomez-Samblas M, Carrasco E, Garrido JM, López-Jaramillo FJ, Santoyo-Gonzalez F, Osuna A.
    Int J Nanomedicine; 2016 Mar 05; 11():4777-4785. PubMed ID: 27698563
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 05; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 17. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.
    Rodallec A, Brunel JM, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, Ciccolini J, Fanciullino R.
    Int J Nanomedicine; 2018 Oct 05; 13():3451-3465. PubMed ID: 29950829
    [Abstract] [Full Text] [Related]

  • 18. Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3).
    Rodallec A, Sicard G, Giacometti S, Carre M, Maia T, Valette M, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R.
    Anticancer Drugs; 2020 Jun 05; 31(5):463-472. PubMed ID: 31895102
    [Abstract] [Full Text] [Related]

  • 19. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer.
    Nunes T, Pons T, Hou X, Van Do K, Caron B, Rigal M, Di Benedetto M, Palpant B, Leboeuf C, Janin A, Bousquet G.
    J Exp Clin Cancer Res; 2019 Jul 12; 38(1):306. PubMed ID: 31299997
    [Abstract] [Full Text] [Related]

  • 20. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.
    Breast Cancer Res Treat; 2010 Aug 12; 122(3):685-97. PubMed ID: 19859802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.